Head-To-Head Survey: Brookline Capital Acquisition (NASDAQ:BCAC) and Sutro Biopharma (NASDAQ:STRO)

Posted by Defense World Staff on May 6th, 2023

Brookline Capital Acquisition (NASDAQ:BCAC – Get Rating) and Sutro Biopharma (NASDAQ:STRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Brookline Capital Acquisition and Sutro Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brookline Capital Acquisition	N/A	-416.32%	-4.75%
Sutro Biopharma	-175.89%	-54.42%	-31.85%

Insider & Institutional Ownership

51.8% of Brookline Capital Acquisition shares are owned by institutional investors. Comparatively, 87.6% of Sutro Biopharma shares are owned by institutional investors. 19.2% of Brookline Capital Acquisition shares are owned by company insiders. Comparatively, 7.4% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Brookline Capital Acquisition has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Valuation and Earnings

This table compares Brookline Capital Acquisition and Sutro Biopharma’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brookline Capital Acquisition	N/A	N/A	-$480,000.00	N/A	N/A
Sutro Biopharma	$67.77 million	4.87	-$119.20 million	($2.37)	-2.31

Brookline Capital Acquisition has higher earnings, but lower revenue than Sutro Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Brookline Capital Acquisition and Sutro Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brookline Capital Acquisition	0	0	0	0	N/A
Sutro Biopharma	0	1	5	0	2.83

Sutro Biopharma has a consensus price target of $17.33, suggesting a potential upside of 216.30%. Given Sutro Biopharma’s higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Brookline Capital Acquisition.

Summary

Sutro Biopharma beats Brookline Capital Acquisition on 6 of the 10 factors compared between the two stocks.

About Brookline Capital Acquisition

(Get Rating)

Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.

About Sutro Biopharma

(Get Rating)

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Receive News & Ratings for Brookline Capital Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brookline Capital Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.